An infant with congenital toxoplasmosis is treated with pyrimethamine and sulfadiazine. The infant develops neutropenia. Leucovorin (folinic acid) is administered to counteract the bone marrow toxicity of pyrimethamine. Why is leucovorin effective in the human host but does not interfere with the drug’s anti-parasitic action on Toxoplasma gondii?